Three-year (36.5 months minimum; 44.0 months median) follow-up results from the phase III CheckMate -9ER trial demonstrated sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma, according to Bristol Myers Squibb and Exelixis Inc.
Stephen BaylinAndrew FeinbergJohns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center researchers Stephen Baylin and Andrew Feinberg were awarded the 2022–2023 Harvey Prize in the field of Science and Technology by the Technion—Israel Institute of Technology.
